^
    15h
    PYX-201-101: A Study of PYX-201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, Pyxis Oncology, Inc | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    micvotabart pelidotin (PYX-201)
    16h
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=96 --> 210 | Trial completion date: Mar 2028 --> Mar 2029 | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • SHR-A2102 • AiRuiLi (adebrelimab)
    17h
    Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) (clinicaltrials.gov)
    P2, N=36, Recruiting, Medical University of South Carolina | Initiation date: Jul 2026 --> Oct 2026
    Trial initiation date
    |
    NavDx®
    17h
    Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P1, N=40, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab)
    17h
    ORARAD: Observational Study of Dental Outcomes in Head and Neck Cancer Patients (clinicaltrials.gov)
    P=N/A, N=613, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    19h
    PDGFRα+/Integrin α2+ Fibroblasts Orchestrate Tumor Budding in Oral Squamous Cell Carcinoma via Mechano-Metabolic Symbiosis: E-Cadherin/Integrin α2β1 Adhesion and Mitochondrial Transfer. (PubMed, Adv Sci (Weinh))
    Targeted inhibition of TNT-mediated mitochondrial transfer markedly suppresses TB in TBO and xenograft models. Together, our results reveal a mechano-metabolic symbiosis between PDGFRα+/integrin α2+ CAFs and OSCC cells that drives TB and provides actionable targets to block this aggressive metastatic precursor.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CDH1 (Cadherin 1) • PDGFA (Platelet Derived Growth Factor Subunit A)
    19h
    MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Meiyouheng (becotatug vedotin)
    21h
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (clinicaltrials.gov)
    P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    22h
    A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. (clinicaltrials.gov)
    P2, N=98, Completed, West China Hospital | Recruiting --> Completed
    Trial completion
    |
    Gilotrif (afatinib) • Tevimbra (tislelizumab-jsgr)
    2d
    Fanconi Anemia as a Window into Premalignant Field Cancerization of the Oral Mucosa. (PubMed, medRxiv)
    The noninvasive brush sampling approach allows repeated measurements, ongoing surveillance, and assessment of prophylactic strategies that may be useful in the prevention of cancers in people with FA and in the general population. Somatic reversion of a pathogenic FANC variant may protect the oral mucosa from DNA repair deficiency and premalignant clonal evolution.
    Journal
    |
    TP53 (Tumor protein P53) • DRD (DNA Repair Deficiency) • FANCB (FA Complementation Group B)
    |
    DDR
    2d
    Extracellular Matrix-Related Prognostic Signature for Head and Neck Squamous Cell Carcinoma via Multi-Algorithm Survival Modeling. (PubMed, Biomark Insights)
    qRT-PCR confirmed elevated expression of key ECM genes, including WNT7A, in tumor tissues, and functional assays showed that WNT7A promotes HNSCC cell proliferation, migration, and invasion. This study developed an ECMS with potential prognostic value, which may complement existing clinical variables for outcome prediction in HNSCC.
    Journal
    |
    WNT7A (Wnt Family Member 7A)
    2d
    Therapeutic targeting of COX-2 in head and neck cancer: Mechanistic and clinical perspectives. (PubMed, Daru)
    In this review, we review COX-2 as a leading therapeutic target for HNSCC with an emphasis on the transition from molecular pathology to clinical application. We prioritize the discussion on (i) established clinical evidence and prognostic value, (ii) robust preclinical data supporting therapeutic combinations, and (iii) emerging strategies such as ferroptosis-sensitization and immune-modulatory approaches.
    Review • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)